PMID- 29221717
OWN - NLM
STAT- MEDLINE
DCOM- 20180926
LR  - 20221207
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 12
IP  - 3
DP  - 2018 May
TI  - Effect of metformin combined with lifestyle modification versus lifestyle 
      modification alone on proinflammatory-oxidative status in drug-naive pre-diabetic 
      and diabetic patients: A randomized controlled study.
PG  - 257-267
LID - S1871-4021(17)30357-0 [pii]
LID - 10.1016/j.dsx.2017.11.003 [doi]
AB  - BACKGROUND: Targeting biomarkers of oxidative-proinflammatory stress may result 
      in improvement of modifiable metabolic syndrome, pre-diabetes and diabetes risk 
      factors and subsequent risk reduction. METHODS: 64 newly diagnosed 
      antihyperglycemic treatment-naive prediabetic and type 2 diabetes mellitus (T2DM) 
      patients were randomly assigned using block design to either metformin combined 
      with therapeutic lifestyle changes (TLC) or TLC alone. Body mass index (BMI), 
      waist circumference, blood pressure, fasting plasma glucose (FPG), glycated 
      hemoglobin (HbA1c), fasting lipid profile, plasma oxidative status and tumor 
      necrosis factor (TNF)-alpha were measured at baseline, after 3 months and after 6 
      months from baseline. RESULTS: Except for HbA1c, baseline values did not differ 
      significantly between the two groups. The post 3-months relative reductions in 
      BMI (P=0.014) and HbA1c (P=0.037) in metformin combined with TLC intervention 
      were significantly greater than those in TLC alone group. TNFalpha plasma levels were 
      decreased significantly vs. baseline by metformin combined with TLC intervention 
      (-22.90+/-46.76%, P=0.01). Conversely, TLC alone basically worsened proinflammatory 
      status (42.40+/-40.82 %), P<0.001. Metformin with TLC treatment effected a 
      therapeutic decrement of the oxidative stress (-15.44+/-35.32%, P=0.029 vs. 
      baseline) unlike TLC alone (61.49+/-122.66%, P=0.01 vs. baseline). Both 
      interventions' effects were sustained in the 6-month follow up periods. 
      CONCLUSION: In both intervention groups, the relative changes in plasma TNFalpha were 
      significantly correlated (P<0.01) with systolic blood pressure and the relative 
      changes in oxidative stress were markedly correlated (P<0.05) with total 
      cholesterol.
CI  - Copyright (c) 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.
FAU - Bulatova, Nailya
AU  - Bulatova N
AD  - School of Pharmacy, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan.
FAU - Kasabri, Violet
AU  - Kasabri V
AD  - School of Pharmacy, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan. Electronic address: v.kasabri@ju.edu.jo.
FAU - Qotineh, Amenah
AU  - Qotineh A
AD  - School of Pharmacy, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan.
FAU - Al-Athami, Taiba
AU  - Al-Athami T
AD  - School of Pharmacy, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan.
FAU - Yousef, Al-Motassem
AU  - Yousef AM
AD  - School of Pharmacy, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan.
FAU - AbuRuz, Salah
AU  - AbuRuz S
AD  - School of Pharmacy, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan; College of Pharmacy, Al Ain University of Science and Technology, AL Ain, 
      Abu Dhabi, United Arab Emirates.
FAU - Momani, Munther
AU  - Momani M
AD  - School of Medicine, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan.
FAU - Zayed, Aymen
AU  - Zayed A
AD  - School of Medicine, The University of Jordan, Queen Rania Street, Amman 11942, 
      Jordan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20171123
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipids)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/analysis
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Inflammation Mediators/*metabolism
MH  - *Life Style
MH  - Lipids/blood
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Prediabetic State/*drug therapy/metabolism/pathology
MH  - Prognosis
MH  - Young Adult
OTO - NOTNLM
OT  - Diabetes
OT  - Metformin
OT  - Prediabetes
OT  - Proinflammatory-oxidative status
OT  - Therapeutics lifestyle changes (TLC)
EDAT- 2017/12/10 06:00
MHDA- 2018/09/27 06:00
CRDT- 2017/12/10 06:00
PHST- 2017/09/28 00:00 [received]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2017/12/10 06:00 [pubmed]
PHST- 2018/09/27 06:00 [medline]
PHST- 2017/12/10 06:00 [entrez]
AID - S1871-4021(17)30357-0 [pii]
AID - 10.1016/j.dsx.2017.11.003 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2018 May;12(3):257-267. doi: 10.1016/j.dsx.2017.11.003. 
      Epub 2017 Nov 23.